Filing Flows › Assembly Biosciences (ASMB) › Q2 2025
Assembly Biosciences (ASMB) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Assembly Biosciences (ASMB) reported revenue of $9.6M for the second quarter 2025 (Q2 2025), +13% from a year earlier and +2% from the quarter before. Operating margin was -115.2%, net loss $10.2M (105.9% of revenue).
Assembly Biosciences, Q2 2025: revenue $9.6M (+13% year over year), operating margin -115.2%, net loss $10.2M, operating cash flow −$16.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.6M | +2% | +13% |
| Operating profit | −$11.1M | — | — |
| Net earnings | −$10.2M | — | — |
| Operating cash flow | −$16.8M | — | — |
What changed
Revenue was $9.6M in Q2 2025, up 13% year over year and up 2% from the previous quarter.
Operating costs exceeded revenue by $11.1M, an operating margin of -115.2%. Total costs fell 0% while revenue rose 13%. The quarter ended with a net loss of $10.2M, wider than the previous quarter's $8.8M loss.
Operating cash flow was −$16.8M. Non-cash charges added back $32K of depreciation and amortization and $834K of share-based compensation. Working capital and other items used $7.4M.
Questions
What was Assembly Biosciences' revenue in the second quarter 2025?
Assembly Biosciences (ASMB) reported revenue of $9.6M for the second quarter 2025 (Q2 2025), +13% from a year earlier and +2% from the quarter before.
Was Assembly Biosciences profitable in the second quarter 2025?
Operating loss was $11.1M (-115.2% of revenue) and net loss $10.2M.